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Abstract
Aim To assess the prognostic relevance of 64-slice com-
puted tomography coronary angiography (CT-CA) and
symptoms in diabetics and non-diabetics referred for
cardiac evaluation.
Methods We followed 210 patients with diabetes type 2
(DM) and 203 non-diabetic patients referred for CT-CA for
ruling out coronary artery disease (CAD). Patients were
without known history of CAD and were divided into four
categories on the basis of symptoms at presentation (none,
atypical angina, typical angina and dyspnoea). Clinical end
points were major cardiac events (MACE): cardiac-related
death, non-fatal myocardial infarction, unstable angina and
cardiac revascularizations. Cox proportional hazard models,
with and without adjustment for risk factors and multipli-
cative interaction term (obstructive CAD × DM), were
developed to predict outcome.
Results DM patients with dyspnoea or who were asymp-
tomatic showed a higher prevalence of obstructive CAD
than non-diabetics (p≤0.01). At mean follow-up of
20.4 months, DM patients had worse cardiac event-free
survival in comparison with non-DM patients (90% vs.
81%, p=0.02). In multivariate analysis, CT-CA evidence of
obstructiveCAD(inDMpatients:HR:6.4;95%CI:2.3–17.5;
p<0.001; in non-DM patients: HR: 7.4; 95% CI: 2.1–26.7;
p=0.002) and the presence of typical angina (in DM
patients: HR: 2.9; 95% CI: 1.3–6.3; p=0.007; in non-DM
patients: HR: 2.7; 95% CI: 1.1–7.1; p=0.03) were indepen-
dent predictors of MACE in both groups. Furthermore, other
independent outcome predictors included dyspnoea
(HR: 3.8; 95% CI: 1.7–8.5; p=0.001), the number of
segments with any CAD (HR: 1.1; 95% CI: 1.001–1.2;
p=0.04) in DM patients and coronary calcium score >100
in non-DM patients (HR: 5.6; 95% CI: 1.4–21.5;
p=0.01). In Cox regression analysis of the overall
population, interaction term obstructive CAD × DM
resulted in non-significance.
Conclusions Among DM patients, dyspnoea carried a high
event risk with a MACE rate four times higher. CT-CA
findings were strongly predictive of outcome and proved
valuable for further risk stratification.
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Diabetes mellitus.Symptoms
Introduction
Type 2 diabetes mellitus (DM) is an increasing health care
problem [1]. The most common cause of death in European
adults with DM is coronary artery disease (CAD) [2].
Several studies have demonstrated that in patients with DM,
the risk of major cardiovascular events is two to four times
higher than that among non-DM patients [3].
The role of non-invasive coronary imaging in diabetic
patients, who typically have a high prevalence of obstruc-
tive CAD [4, 5], is not to simply document the presence of
coronary atherosclerosis, but to identify those patients with
more extensive disease. In these patients, further functional
testing could assess the haemodynamic significance of the
demonstrated CAD. Despite the well-validated negative
predictive value of stress imaging techniques after a normal
stress test [6, 7], diabetic patients have a more than two-fold
increased likelihood of myocardial infarction or cardiac
death compared with non-diabetic patients [8]. Therefore,
an extended risk assessment is important in this population
in order to identify those patients at particular risk of future
cardiac events and outline goals for the long-term manage-
ment strategy. It is generally accepted that the character of
the symptoms in patients with suspected angina is central to
clinical diagnosis and risk assessment [9–11]. A difficulty
in the assessment of patients with DM is that symptoms of
myocardial ischaemia are often absent or atypical (shortness
of breath) [12].
Recently, multislice computed tomography coronary
angiography (MSCT-CA) has emerged as a powerful tool
for ruling out CAD, especially in patients with an
intermediate likelihood of CAD or when testing for
ischaemia is equivocal [13, 14]. Previous studies of
MSCT-CA have focused primarily on its diagnostic
accuracy for the detection of obstructive CAD in compar-
ison with invasive coronary angiography and demonstrated
a high sensitivity and negative predictive value close to
100% [15]. The ability to detect not only coronary stenosis
but also the non-obstructive coronary atherosclerotic plaque
in a non-invasive fashion makes MSCT-CA imaging a
potentially valuable tool for risk stratification. Over the past
3 years, the clinical value of MSCT-CA to determine
prognosis has begun to be investigated [16–22]. However,
most of these studies have focused on patients with either a
suspected or documented history of CAD [16–19].
The goal of the present study was to evaluate the
prognostic implications of MSCT-CA findings as well as
presenting symptoms in diabetic patients with suspected
CAD compared with non-diabetic individuals who un-
derwent MSCT-CA with the aim of ruling out CAD.
Furthermore, we sought to identify how the MSCT-CA
findings can be combined with symptom evaluation to
further refine the prognostic power of MSCT-CA and,
thus, allow for the more effective identification of
patients at relatively high (or low) risk of future cardiac
events.
Materials and methods
Study group The study group consisted of 433 consecutive
eligible patients who were referred to our institution from
January 2005 to December 2005 for further evaluation of
suspected CAD on the basis of symptoms, elevated risk
profile or abnormal diagnostic test results. All patients were
without known history of CAD [defined as chart docu-
mented >30% luminal narrowing in any vessel on previous
CAG, acute myocardial infarction (MI), a previous history
of MI, coronary artery bypass graft surgery or percutaneous
coronary intervention]. The study was a single-centre
prospective observational study. In all patients MSCT-CA
was performed on the basis of symptoms and/or elevated
risk profile in addition to standard clinical diagnostic
workup involving exercise electrocardiogram, myocardial
scintigraphy and echocardiography.
From the 433 patients who had an MSCT-CA, 20 (5%)
were lost to follow-up, resulting in a final study cohort of
413 individuals. Of these 413 patients, 210 had DM, while
203 were without DM. The enrolment was performed
consecutively in each group (DM and non-DM). At the
baseline examination, a standardised data collection form
was filled out by the duty physician (F.C.; E.M.). Baseline
demographic variables, CAD risk factors and clinical signs
were collected.
Diabetes was defined as a fasting plasma glucose level
of≥126 mg/dl treated currently with diet intervention,
oral glucose-lowering agents or insulin [23]. The follow-
ing risk factors were acquired for all subjects at the
baseline examination: systemic hypertension (defined as
blood pressure of≥140/90 mmHg or the use of antihyper-
tensive medication) [24]; hypercholesterolaemia (defined
as a total cholesterol level of≥200 mg/dl or treatment with
lipid-lowering drugs) [25]; obesity (body mass index
of≥30 kg/m
2)[ 26]; positive family history of CAD
(defined as the presence of CAD in a first-degree female
[<65 years] or male [<55 years] relative [27]); and
smoking (defined as previous or current smoking).
Patients were divided into four categories according to
their self-reported symptoms of chest pain and dyspnoea at
the time of testing. Typical angina was defined as chest pain
that was substernal, occurring during stress and resolving
within 10 min after rest or the receipt of nitroglycerin,
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pain symptoms that did not fall into this typical category
were further classified as having atypical angina. Among
patients without chest discomfort, patients who experienced
shortness of breath were classified as having dyspnoea; the
remainder were classified as asymptomatic. Dyspnoea was
not coded in patients with chest pain.
Pre-test likelihood of CAD was determined in every
patient according to a modification of the Diamond-
Forrester algorithm, as published by Morise et al. [28].
These patients were further categorised into low probability
(score 0–8), intermediate probability (score 9–15) and high
probability (score >15).
Inclusion criteria for the imaging were regular heart rate
(spontaneous or β-blocker-induced) of less than 70 beats
per minute (bpm) and the ability to hold a breath for at least
12 s. Exclusion criteria for the imaging were a high heart
rate (>70 bpm), previous allergic reaction to iodine contrast
medium, renal insufficiency (creatinine clearance <60 ml/min),
pregnancy, respiratory impairment and unstable clinical status.
The study was approved by the institutional review
board, and informed consent was obtained from all
participating patients before testing.
MSCT protocol All examinations were performed with a
64-slice CT scanner (Sensation 64, Siemens, Forchheim,
Germany) as described elsewhere [15]. First a non-contrast-
enhanced, prospectively ECG-triggered CT was performed.
This CT was used to calculate the Agatston calcium score
(CACS). Afterwards we performed MSCT-CA, after an
intravenous injection of a bolus (80–100 ml at 4–6 ml/s) of
non-ionic iodinated contrast agent (iomeprol 400 mg/ml,
Iomeron, Bracco, Italy) followed by a saline chaser (50 ml
at 4–6 ml/s). If the heart rate was >65 bpm, additional
intravenous beta-blockers (atenolol 5–10 mg) were provided
whentolerated.In308patients(75%)sublingualnitroglycerin
(0.3 mg) was also administered immediately before the
examination to optimise visualisation of small coronary
vessels.
Tube current modulation was not used; the mean
radiation exposure using this imaging protocol was
685 mGy (range 515–1,052 mGy), corresponding to an
effective dose of 11.6 mSv (range 8.7–17.9 mSv).
MSCT data analysis With dedicated software (CaScore,
Siemens, Germany), an overall CACS was recorded for
each patient based on the scoring algorithm of Agatston et
al. [29], where coronary artery calcium was identified as a
dense area greater than 1 mm
2 in the coronary artery
exceeding the threshold of 130 Hounsfield units. All
MSCT-CA investigations were evaluated by two experi-
enced observers who were unaware of the clinical history of
the patients, using a standard approach to analysis. In the
case of disagreement, a joint reading was performed and a
consensus decision was reached. All 16 coronary segments
as established in the American Heart Association classifi-
cation [30] were considered in the analysis. First, each
segment was rated as interpretable or not interpretable.
Thereafter, all interpretable segments were evaluated for the
presence of any atherosclerotic plaque [31] using axial
images and curved multiplanar reconstructions. Subse-
quently, the lesion was classified visually as obstructive
(>50% luminal narrowing) or non-obstructive (≤50%
luminal narrowing). For every patient, the number of
diseased segments with obstructive and non-obstructive
CAD was recorded. Finally, a total plaque score (out of 16)
including all affected segments was calculated in each
patient.
Follow-up All patients were followed up for a minimum of
6 months after the MSCT-CA examination. One of the
study investigators (S.S.; E.M.; F.C.) performed a telephone
interview with each patient, with his or her direct relative or
with the referring physician to ascertain follow-up informa-
tion and screen for occurrence of clinical events or coronary
revascularizationprocedures,anychangeinclinicalstatusand
hospital admission. To confirm the obtained information,
electronic hospital records of all patients were carefully
screened for the occurrence of clinical events.
The principal study end point was the composite of
major adverse cardiac events (MACE), which included the
need for elective revascularization (including during the
initial assessment) and hard cardiac events: cardiac death,
non-fatal MI and unstable angina requiring hospitalization
(UA). Deaths that could not be classified were considered
cardiac-related. MI was defined based on criteria of typical
chest pain, elevated cardiac enzyme levels and typical
changes on the electrocardiogram [32]. The decision
regarding the need for coronary revascularization and the
method of revascularization (coronary artery bypass grafting
or a percutaneous coronary intervention) was made by the
referring cardiologist on an individual patient basis.
Statistical analysis Continuous variables are expressed as
mean values (±SD) or median and interquartile range (25%
and 75% percentiles), where appropriate. Differences
between groups were compared using the Student’s t and
chi-squared tests, as appropriate.
Cumulative event rates of the composite MACE (cardiac
death, non-fatal MI, UA and the need for revascularization)
were estimated using the Kaplan-Meier method and
compared using the log-rank test. A parallel survival model
was constructed in which patients with early coronary
revascularization (<60 days after the MSCT-CA examination)
were excluded from the analysis. Patients undergoing
coronary revascularization were censored at the time of the
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only the first event was counted. Survival times of patients
still alive or disease-free were censored with the median
follow-up period.
The association of selected variables with MACE was
assessed using Cox’s proportional hazards survival model
involving univariate and forward stepwise multivariate
procedures. A significance level of 0.05 was required for
an MSCT-CA variable to be included in the multivariate
model, whereas a level of 0.1 was the cutoff value for
exclusion. Multivariate analysis was corrected for the
baseline characteristics with p≤0 . 1i nt h eu n i v a r i a t e
analysis. Hazard ratios with the corresponding 95%
confidence intervals (CI) were estimated. Potential interac-
tion (effect modification) between obstructive CAD and
diabetes was evaluated by adding a multiplicative interac-
tion term (obstructive CAD × diabetes) to the Cox model.
The predictive value of CACS was assessed using binary
cutoff values (CACS≤100, CACS>100, CACS>400). The
incremental value of MSCT-CA was determined by
calculating the change in global χ
2 with respect to
prognosis (Cox model) after adding the MSCT-CA varia-
bles to the pre-imaging information (Morise score) and
significant calcium score (CACS>100). Annualized event
rates were expressed as a proportion of the number of
patients having MACE divided by the number of patient-
years’ follow-up.
Receiver-operating characteristic (ROC) analysis was
performed to calculate the area under the curve (AUC) to
determine whether the total plaque score provided incre-
mental value in predicting MACE over and above that
provided by the pre-test likelihood prediction model
according to Morise.
Statistical analysis was performed with SPSS (version
12.0, SPSS, Chicago, IL) and MedCalc (version 9.3.0.0.,
MedCalc Software, Mariakerke, Belgium) software. Signif-
icance was set at p<0.05.
Results
All 413 patients included in the study underwent MSCT-CA
without complications. The clinical and demographic charac-
teristics of the patients are shown in Table 1.O v e r a l l ,6 1
(15%) patients had a low, 302 (73%) had an intermediate
and 50 (12%) had a high pre-test likelihood of CAD. The
two groups studied were comparable with regard to the
baseline characteristics, but differed significantly with regard
to BMI, smoking history and pre-test likelihood of CAD
(low and high categories). Most DM and non-DM patients
were symptomatic (66% vs. 72%, respectively, p n.s.), with
atypical angina the more frequent presenting symptom (36%
vs. 38%, respectively, p n.s.).
MSCT-CA findings A total of 92 (1%) coronary segments
were considered to be of non-diagnostic quality (n=80 with
motion artefacts due to elevated heart rate, n=12 with
extensive calcification) and were excluded from evaluation.
Total plaque burden was therefore evaluated in 6,227
segments. As shown in Table 2, patients with DM had
twice the prevalence of obstructive CAD compared with
non-diabetic patients (36% vs. 17%, respectively, p<
0.0001), and a lower prevalence of normal coronary arteries
(28% vs. 37%, respectively) and non-obstructive CAD
(36% vs. 46%, respectively), although these differences
were non-significant. The total Agatston calcium score,
which reflects plaque burden, was higher in diabetic
patients than in normal patients (351 vs. 146, respectively,
p<0.001). Furthermore, diabetic patients showed a higher
prevalence of CACS>400 (24% vs. 11%, respectively, p=
0.001) and a higher average number of diseased coronary
segments (4.5 vs. 2.8, respectively, p<0.0001), with either
obstructive (0.9 vs. 0.3, p<0.0001) or non-obstructive (3.7
vs. 2.5, p<0.001) CAD.
Prevalence of CAD on MSCT-CA in DM and non-DM
patients stratified for the type of presenting symptom is
provided in Fig. 1. In both DM and non-DM patients, the
highest prevalence of obstructive CAD was documented in
patients with typical angina (57.7% vs. 56.5%, respectively,
p=n.s.).
There was a higher prevalence of obstructive CAD in DM
patients than in non-DM patients in all symptom categories,
although this difference was only significant in asymptomatic
patients (37.5% vs. 10.7%, respectively, p=0.001) and
patients with dyspnoea (35.1% vs. 10.6%, respectively,
p=0.01).
Follow-up results During a mean follow-up period of
20.4±5.2 months (median: 580 days, interquartile range:
420-686 days), 37 MACE occurred in diabetic patients
compared with 20 in non-diabetic patients (18% vs. 10%,
respectively, p=0.03). Excluding revascularization, a total
of ten hard cardiac events were observed, eight hard events
(fatal acute MI, n=2; non-fatal acute MI, n=3; UA
requiring hospitalization, n=3) among DM patients (4%)
and two hard events (non-fatal acute MI, n=2) among non-
DM patients (1%).
Of the 37 diabetic patients suffering cardiac events, 31
(84%) had obstructive disease, while 6 (16%) had non-
obstructive disease (p<0.0001). Conversely, the 20 non-
diabetic patients suffering cardiac events comprised 16
(80%) with obstructive disease and 4 (20% with non-
obstructive disease (p<0.0001).
A total of 33 (16%) diabetic and 18 (9%) non-diabetic
patients (p=0.04) underwent coronary revascularization
(10 surgical and 41 percutaneous coronary interventions).
Four revascularizations were performed after the occur-
28 Insights Imaging (2011) 2:25–38rence of a hard cardiac event in four DM patients. Thirty-
one (61%) patients underwent revascularization because of
single-vessel disease. Twenty-nine (57%) patients under-
went revascularization within 2 months of the MSCT-CA
examination.
Annualized MACE rates in DM and non-DM patients
stratified with regard to the type of presenting symptoms
are provided in Table 3. In both DM and non-DM patients,
the highest annual MACE rate was documented in patients
with typical angina (26.3% vs. 23.2%, respectively, p=n.s.).
Furthermore, in both DM and non-DM patients, those with
typical angina had significantly more MACE than asymp-
tomatic patients (p<0.01) or those with atypical angina
(p<0.05). Significant difference was also observed among
DM patients with dyspnoea and asymptomatic DM patients
(20.2% vs. 5.5%, respectively, p=0.04).
Survival analysis As shown in Fig. 2, DM patients had a
worse prognosis than non-DM patients (18.7% vs. 9.9%,
respectively, p=0.02). In both DM and non-DM patients a
higher MACE rate occurred in patients with obstructive
CAD (42.7% vs. 45.7%, respectively) compared with
patients with non-obstructive CAD (9.8% vs. 4.3%) or
normal coronary arteries (0% vs. 0%) (p<0.0001) (Fig. 3).
After stratification in terms of presenting symptoms
(Fig. 4), the MACE rate was higher in both DM and non-
DM patients with typical angina compared with the other
clinically relevant categories (p<0.0001). Notably, among
DM patients, the MACE rate was significantly higher in
patients with dyspnoea than in asymptomatic patients
(27.9% vs. 8.7%, respectively, p=0.005), and after com-
paring patients with dyspnoea with patients with atypical
angina the difference was nearly significant (27.9% vs.
13.6%, respectively, p=0.05). Moreover, among patients
with dyspnoea, the MACE rate was higher in DM patients
than in non-DM patients (27.9% vs. 8.5%, respectively,
p=0.02).
After excluding early revascularizations (<60 days after
MSCT-CA examination, n=29), survival analysis of MACE
(n=28) demonstrated that the event rate remained higher
among DM patients than among non-DM patients (11.6%
vs. 3.0%, respectively, p=0.001). Moreover, the presence of
obstructive CAD and typical angina remained significantly
associated with outcome in both DM and non-DM patients
(p<0.001).
Outcome prediction Univariate and multivariate predictors
of MACE for all patients and for DM and non-DM patients
Table 1 Baseline characteristics of the overall population and of diabetics compared with non-diabetics
Overall population (n=413) Diabetics (n=210) Non-diabetics (n=203) p Value*
Clinical characteristics
Age (years; mean [SD]) 61 (11) 60 (10) 62 (11) 0.06
Male gender (%) 262 (63) 133 (63) 129 (63) 0.95
BMI (kg/m²; mean [SD]) 27 (2) 28 (4) 26 (3) <0.0001
Mean heart rate (bpm; mean [SD]) 61 (10) 62 (10) 61 (10) 0.31
Follow-up (months; mean [SD]) 20 (6) 20 (8) 21 (3) 0.16
Risk factors
N. of risk factors (mean [SD]) 2.3 (1.2) 2.3 (1.2) 2.2 (1.1) 0.38
Hypertension 272 (66) 144 (69) 128 (63) 0.28
Hypercholesterolaemia (%) 200 (48) 97 (46) 103 (51) 0.41
Obesity (BMI≥30 kg/m²) (%) 117 (28) 78 (37) 39 (19) 0.0001
Current smoking (%) 144 (35) 63 (30) 81 (40) 0.04
Family history of CAD (%) 200 (48) 105 (50) 95 (47) 0.58
Symptoms
Asymptomatic (%) 128 (31) 72 (34) 56 (28) 0.17
Typical angina pectoris (%) 49 (12) 26 (12) 23 (11) 0.86
Atypical angina pectoris (%) 152 (37) 75 (36) 77 (38) 0.71
Dyspnoea (%) 84 (20) 37 (18) 47 (23) 0.20
Pre-test likelihood of CAD
#
Low (%) 61 (15) 19 (9) 42 (21) 0.001
Intermediate (%) 302 (73) 148 (71) 154 (76) 0.26
High (%) 50 (12) 43 (20) 7 (3) < 0.0001
Data are presented as mean (standard deviation) or number (percentage). CAD=coronary artery disease; BMI=body mass index.
#According to the
scoring method of Morise. *Comparison between diabetics and non-diabetics
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CACS>100 and obstructive CAD were independently
associated with MACE in all patients (n=413) (Table 4).
The interaction term obstructive CAD × diabetes was
highly significant (p<0.0001) at univariate analysis and
suggested that obstructive CAD and DM were synergistic
for predicting survival. However, when incorporated in the
multivariate Cox proportional hazards regression analysis,
the interaction term was not significant.
After adjusting for baseline risk factors and presenting
symptoms obtained before MSCT-CA, the presence of
obstructive CAD remained the strongest predictor of events
for both DM and non-DM patients, thus yielding incre-
mental value over pre-imaging data (Table 5). Furthermore,
typical angina was a multivariate prognostic indicator for
both groups (p<0.05), while the presence of dyspnoea was
also a strong independent predictor only for DM patients
(p=0.001), together with increasing age (p=0.03) and the
number of segments with any CAD (p=0.04). The presence
of CACS >100 remained a significant outcome predictor
only for non-diabetics (p=0.01).
The incremental value of coronary plaque content over
traditional risk assessment was evaluated by ROC analysis
(Fig. 5). The AUC for the total plaque score predicting
MACE was significant in all patients (0.83, CI 0.78–0.87,
p<0.0001) and in both non-diabetics (0.84, CI 0.78–0.90,
p<0.0001) and diabetics (0.81, CI 0.74–0.88, p<0.0001).
Similarly, the AUC for pre-test likelihood predicting MACE
Overall population
(n=413)
Diabetics
(n=210)
Non-diabetics
(n=203)
p Value*
Patients
Absence of CAD (%) 134 (32) 59 (28) 75 (37) 0.07
Non-obstructive CAD (%) 169 (41) 76 (36) 93 (46) 0.06
Obstructive CAD (%) 110 (27) 75 (36) 35 (17) <0.0001
Obstructive CAD in:
LM/LAD 76 (18) 54 (26) 22 (11) <0.001
RCA 43 (10) 32 (15) 11 (5) 0.001
CXA 37 (9) 25 (12) 12 (6) 0.05
Single-vessel disease (%) 72 (17) 46 (22) 26 (13) 0.02
Multivessel disease (%) 38 (9) 29 (14) 9 (4) 0.002
Total Agatston score 250.7 (599.7) 351.6 (743.4) 146.2 (374.5) <0.001
CACS≤100 277 (67) 132 (63) 145 (71) 0.08
CACS>100 136 (33) 78 (37) 58 (29) 0.08
CACS>400 73 (18) 50 (24) 23 (11) 0.001
Segments
No. of diseased segments 3.7 (4.2) 4.5 (4.6) 2.8 (3.5) <0.0001
No. of segments with
Non-obstructive plaque 3.1 (3.7) 3.7 (4.0) 2.5 (3.2) <0.001
Obstructive plaque 0.6 (1.4) 0.9 (1.8) 0.3 (0.8) <0.0001
Table 2 Multislice computed
tomography coronary angiogra-
phy findings of the overall
population and of diabetics
compared with non-diabetics
Data are presented as mean
(standard deviation) or number
(percentage). CAD=coronary
artery disease; LM=left main
coronary artery; LAD=left
anterior descending coronary
artery; RCA=right coronary
artery; CXA=left circumflex
coronary artery; CACS, coro-
nary artery calcium score.
*Comparison between diabetics
and non-diabetics
Fig. 1 Clustered bar graph
showing the association
between symptom categories
and the prevalence of normal/
non-obstructive CAD
and obstructive CAD in DM
and non-DM patients.
CAD=coronary artery disease;
DM: diabetes mellitus
30 Insights Imaging (2011) 2:25–38was significant in all patients (0.69, CI 0.63–0.75, p<
0.0001) and in both non-diabetics (0.67, CI 0.57–0.76, p=
0.01) and diabetics (0.68, CI 0.59–0.73, p=0.001).
The difference in AUC between the total plaque score
and the pre-test likelihood of CAD was significant in the
overall population (0.14, p=0.0001) and in both subgroups
(diabetics: 0.13, p=0.01; non-diabetics: 0.17, p=0.004).
To determine the independent prognostic value of
MSCT-CA over calcium score, multivariate models were
created including MSCT-CA variables corrected for clinical
baseline (Morise Score) and CACS>100. Figure 6 shows
that CACS >100 has a significant incremental prognostic
value over the Morise score (p<0.0001); a further signif-
icant incremental prognostic value over the Morise score
plus CACS >100 was observed with the addition of all
MSCT-CA variables. These results suggest that MSCT-CA
may provide additional prognostic information.
Discussion
Individual pre-test risk stratification of patients who are
referred for MSCT-CA for suspected CAD primarily relies
on the use of algorithms, i.e., the Framingham risk score
[33] or the Morise score [28], and evaluation of chest
symptoms. According to the recent recommendations from
the European Society of Cardiology [14] regarding the
utility of MSCT-CA, most of our study population was
symptomatic and had an intermediate likelihood of CAD.
Fig. 2 Kaplan-Meier survival curves for MACE in diabetics and non-
diabetics. MACE=major adverse cardiac events, indicates cardiac
death, non-fatal infarction, unstable angina requiring hospitalization
and cardiac revascularizations
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Insights Imaging (2011) 2:25–38 31Although there was a higher prevalence of smoking among
non-diabetics, diabetic patients had a greater overall baseline
riskfactorprofile,asdemonstratedbya highermeanBMI and
prevalence of obesity. Furthermore, patients with DM had a
larger plaque burden as CAD tended to be more severe and
extensive, resulting in multivessel disease being more
frequently diagnosed. These findings have a pathological
basis, as demonstrated by previous autopsy study in which,
among individuals without clinical CAD, DM was associated
with a global coronary disease burden and a prevalence of
high-grade atherosclerosis similar to that observed among
non-diabetic persons with clinical CAD [4].
In our study, after stratification in terms of presenting
symptoms, DM and non-DM patients with typical angina
had the highest prevalence of obstructive CAD compared
with patients with other clinical presentations. This finding
is in agreement with the work by Diamond and Forrester
[34], in which patients with typical angina had a higher
likelihood of angiographic CAD than patients with atypical
or non-anginal chest pain.
Moreover, in our study DM patients more frequently
underwent coronary revascularization and fared worse than
non-diabetic patients.
On multivariate survival analysis, the presence of
obstructive CAD was independently associated with out-
come in both DM and non-DM patients. Interestingly, the
diabetic state alone was not a significant independent
predictor for vascular events in Cox regression analysis of
Fig. 3 Kaplan-Meier survival
curves for MACE in diabetics
and non-diabetics stratified for
the severity of CAD on
MSCT-CA: Absence of plaques,
non-obstructive disease
and obstructive disease.
MACE=major adverse cardiac
events, indicates cardiac death,
non-fatal infarction, unstable
angina requiring hospitalization
and cardiac revascularizations.
CAD=coronary artery disease;
MSCT-CA=multislice
computed tomography coronary
angiography
Fig. 4 Kaplan-Meier survival curves for MACE in diabetics and non-
diabetics stratified for the type of presenting symptom. MACE=major
adverse cardiac events, indicates cardiac death, non-fatal infarction,
unstable angina requiring hospitalization and cardiac revasculariza-
tions. CAD=coronary artery disease; MSCT-CA=multislice computed
tomography coronary angiography
32 Insights Imaging (2011) 2:25–38overall population adjusting for other cardiovascular risk
factors, although it approached significance on univariate
analysis. However, the presence of significant stenosis was a
strong independent predictor of vascular events with an odds
ratio of 8.9 (4.0–19.59), p<0.001. Also, an interaction term
obstructive CAD × diabetes resulted in non-significance
indicating that only the presence of significant CAD, but not
that of diabetes, affected vascular events. Therefore,
although cardiac risk was higher in the sample of diabetic
patients than in non-diabetic patients, diabetes per se was not
a CAD risk equivalent. This may reflect the greater
importance of MSCT-CA evidence of obstructive CAD as
well as symptomatic status for the prediction of cardiac
events [35, 36]. Additionally both DM and non-DM patients
with non-obstructive CAD showed a higher event rate than
patients with normal coronary arteries. It is known that
almost two thirds of acute coronary syndromes are attribut-
able to non-obstructive lesions (<50%) owing to plaque
disruption with superimposed thrombosis, whereas only 14%
are attributable to a critical stenosis (>70%) [37]. Impor-
tantly, our patients without CAD had a 100% event-free
survival at mid-term follow-up. Therefore, since ideal risk
stratification should identify patients who do not require
further intervention, MSCT-CA may possess this attribute.
Finally, we demonstrated that coronary plaque score
showed superior outcome classification ability when com-
pared with the pre-test likelihood prediction model.
Moreover, MSCT-CA variables provided significant incre-
mental prognostic value over calcium score. This result is
comparable to a recent study that demonstrated that MSCT-
CA provides additional information to calcium score
regarding stenosis severity and plaque composition [38].
All patients (n=413)
Univariate analysis Multivariate analysis
HR (95% CI) p Value HR (95% CI) p Value
Clinical characteristics
Age (>65 years) 2.80 (1.64–4.79) <0.001
Male gender 1.35 (0.77–2.38) 0.29
DM 1.82 (1.06–3.14) 0.03
Hypertension 2.02 (1.07–3.80) 0.03
Family history 1.63 (0.96–2.77) 0.07
Smoking 1.84 (1.10–3.09) 0.02
Hypercholesterolaemia 1.76 (1.03–2.98) 0.04
Obesity 0.88 (0.49–1.59) 0.68
Symptoms
Asymptomatic 0.34 (0.16–0.71) 0.004
Typical angina pectoris 5.05 (2.95–8.63) <0.0001 2.70 (1.46–4.97) 0.001
Atypical angina pectoris 0.53 (0.29–0.97) 0.04
Dyspnoea 1.62 (0.91–2.88) 0.10 3.08 (1.55–6.09) 0.001
MSCT characteristics
CACS >100 11.39 (5.7–22.6) <0.0001 3.5 (1.62–7.57) 0.001
CACS >400 6.11 (3.6–10.3) <0.0001
Absence of plaques 0.031 (0.006–0.17) <0.001
Non-obstructive CAD 0.28 (0.14–0.56) <0.001
Obstructive CAD 16.7 (8.46–33.1) <0.0001 8.9 (4.0–19.59) <0.0001
Single-vessel obstructive
CAD 5.53 (3.3–9.32) <0.0001
Multivessel obstructive CAD 6.22 (3.6–10.7) <0.0001
No. of segments with
Any CAD 1.22 (1.16–1.28) <0.0001
Non-obstructive CAD 1.18 (1.12–1.24) <0.0001
Obstructive CAD 1.31 (1.22–1.41) <0.0001
Interaction term
Obstructive CAD × DM 6.71 (4.0–11.3) <0.0001
Table 4 Univariate and multi-
variate predictors of total cardiac
events in all patients
CAD=coronary artery disease;
HR=hazard ratio; CACS: Coro-
nary Artery Calcium Score;
DM=diabetes mellitus;
CI=confidence interval
Insights Imaging (2011) 2:25–38 33This additional information was shown to translate into
incremental value for risk stratification.
In our study, both DM and non-DM patients with typical
angina were at higher risk of adverse outcomes than
patients among the other clinically relevant categories.
Our results are similar to those reported in previous
prognostic studies in patients undergoing exercise testing
[39, 40]. Interestingly, in our study we registered two
cardiac deaths among asymptomatic DM patients with
obstructive CAD on MSCT-CA. Moreover, these patients
showed more than three times the prevalence of obstructive
CAD among asymptomatic non-DM patients. It is known
that ischaemic chest pain is blunted in DM. Myocardial
ischaemia or myocardial infarction may be associated with
only mild symptoms or may be totally silent owing to
autonomic neuropathy. Silent ischaemia, in particular, is a
concern in about 20% of DM patients [41, 42].
In our study dyspnoea has emerged a strong prognostic
indicator among DM patients. Although dyspnoea is the
most common complaint of patients with cardiopulmonary
diseases, there has been only limited investigation of its
prognostic significance among patients referred for cardiac
evaluation. A previous study conducted with myocardial
perfusion single-photon emission computed tomography
(SPECT) demonstrated that DM patients with shortness of
breath and no history of CAD had a significantly worse
outcome and a higher likelihood of ischaemic abnormalities
than those who had typical angina pectoris or who were
asymptomatic [43]. Furthermore, another study involving a
large cohort of patients undergoing SPECT showed that
among patients with no known history of CAD, those with
dyspnoea had four times the risk of sudden death from
cardiac causes of asymptomatic patients and more than twice
the risk of patients with typical angina [44]. In this prognostic
study, interestingly, patients with dyspnoea had a significantly
higher rate of diabetes than those in other clinical subgroups.
These findings complement the results of two earlier
studies that investigated the prognostic role of dyspnoea in
Table 5 Univariate and multivariate predictors of total cardiac events in diabetics and non-diabetics
Diabetics (n=210) Non-diabetics (n=203)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Clinical characteristics
Age (>65 years) 3.80 (1.94–7.44) <0.001 2.22 (1.09–4.51) 0.03 1.97 (0.81–4.80) 0.14
Male gender 0.89 (0.46–1.73) 0.74 3.41 (1.0–11.58) 0.05
Hypertension 2.53 (1.06–6.03) 0.04 1.39 (0.54–3.59) 0.50
Family history 1.54 (0.80–2.95) 0.19 1.76 (0.72–4.28) 0.22
Smoking 2.03 (1.07–3.87) 0.03 1.87 (0.78–4.49) 0.16
Hypercholesterolaemia 1.79 (0.93–3.45) 0.08 1.85 (0.74–4.61) 0.19
Obesity 0.91 (0.47–1.79) 0.79 0.45 (0.10–1.91) 0.28
Symptoms
Asymptomatic 0.34 (0.14–0.81) 0.016 0.28 (0.06–1.19) 0.09
Typical angina pectoris 3.29 (1.63–6.65) <0.001 2.91 (1.34-6.31) 0.007 9.47 (3.93–22.8) <0.0001 2.75 (1.06–7.1) 0.03
Atypical angina pectoris 0.63 (0.30–1.29) 0.21 0.39 (0.13–1.17) 0.09
Dyspnoea 2.05 (0.99–4.24) 0.05 3.8 (1.7–8.51) 0.001 0.83 (0.28–2.48) 0.74
MSCT characteristics
CACS>100 8.68 (3.82–19.7) <0.0001 16.4 (4.86–55.9) <0.0001 5.57 (1.44–21.5) 0.01
CACS>400 6.46 (3.33–12.54) <0.0001 4.65 (1.86–11.61) 0.001
Absence of plaques 0.03 (0.001–0.5) 0.02 0.02 (0.001–0.93) 0.04
Non-obstructive CAD 0.30 (0.13–0.73) 0.01 0.29 (0.09–0.85) 0.02
Obstructive CAD 12.19 (5.10–29.13) <0.0001 6.38 (2.33–17.5) <0.001 23.7 (7.89–70.9) <0.0001 7.43 (2.1–26.7) 0.002
Single-vessel obstructive CAD 4.04 (2.12–7.71) <0.0001 8.12 (3.39–19.46) <0.0001
Multivessel obstructive CAD 4.25 (2.19–8.25) <0.0001 11.46 (4.38–29.9) <0.0001
No. of segments with
Any CAD 1.22 (1.14–1.3) <0.0001 1.1 (1.001–1.2) 0.04 1.21 (1.11–1.31) <0.0001
Non-obstructive CAD 1.18 (1.10–1.25) <0.0001 1.17 (1.07–1.28) 0.001
Obstructive CAD 1.24 (1.14–1.36) <0.0001 2.1 (1.6–2.6) <0.0001
CAD=coronary artery disease; HR=hazard ratio; CI=confidence interval
34 Insights Imaging (2011) 2:25–38patients undergoing stress echocardiography or exercise
stress testing [45, 46]. One potential explanation is that,
even in the absence of chest pain, the presence of
symptoms such as dyspnoea may serve as an angina
equivalent or a marker of underlying cardiac disease [47].
Study limitations
This study has several potential limitations. First, there was
the enrolment bias that led to such a high proportion of
diabetics.
Second, complete information concerning the degree of
metabolic control of DM and the status of secondary organ
involvement and of autonomic dysfunction was missing.
This limitation was mainly due to the exploratory nature of
the study, which was aimed at investigating the prognostic
role of MSCT-CA and symptoms on outcome in “real
world” DM patients without known CAD rather than on the
degree of diabetes control.
Another limitation of the study is that we included in the
multivariate analysis patients who underwent early revas-
cularization procedures (<60 days after the examination)
that are generally performed as a direct consequence of the
MSCT-CA findings, such as evidence of obstructive CAD.
Conversely, decisions to perform late revascularization
procedures (≥60 days after MSCT-CA examination) are
usually not significantly influenced by the results of the
examination, but instead by worsening clinical status, such
Fig. 6 Bar graphs illustrating the incremental prognostic value
(depicted by global χ² value on the y-axis) of plaque burden on
MSCT-CA (defined as the number of diseased segments or number of
segments with obstructive CAD) and obstructive CAD (>50%
stenosis) on MSCT-CA over clinical baseline (Morise score) and
CACS. CACS has a significant incremental prognostic value over
Morise score (#). A further incremental prognostic value over Morise
score and CACS was observed with the addition of MSCT-CA (*).
CAD=coronary artery disease; MSCT-CA=multislice computed to-
mography coronary angiography; CACS, coronary artery calcium
score
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Fig. 5 Receiver-operating characteristic curve analysis demonstrating the incremental ability of total plaque score over pre-test likelihood in
predicting MACE in all patients, non-diabetics and diabetics. AUC, area under the curve; MACE, major adverse cardiac eventsthat late revascularizations represent a surrogate for disease
progression. However, it is worthwhile noting that all
decisions regarding revascularization were based on symp-
toms and/or the presence of concomitant ischaemia on non-
invasive testing, rather than on the arbitrary evidence of
obstructive CAD on MSCT-CA. Furthermore, in our
study, a parallel survival model for MACE excluding
early revascularizations demonstrated that DM patients
remained associated with worse outcome; moreover, the
presence of obstructive CAD and typical angina
remained associated with outcome in both DM and
non-DM patients. Therefore, our results do not seem to
be affected by treatment bias.
Another shortcoming could be that men and women may
report symptoms differently; therefore, the risk of cardio-
vascular events may be affected by gender differences
among symptom categories.
Furthermore, the reproducibility of the self-reported
information about presenting symptoms was not evaluated.
Pulmonary and cardiac diseases are responsible for almost
all cases of dyspnoea, and historical or functional testing
information regarding lung disorders was not systematically
obtained. A systematic analysis of the left ventricular
ejection fraction or exercise-induced dynamic functional
mitral regurgitation as a mechanism for inducing dyspnoea
was not performed. Moreover, anaemia and psychogenic
causes of dyspnoea were not evaluated.
As patients were categorised as having dyspnoea if they
had no history of concomitant chest discomfort, we were
unable to evaluate the potential interaction between
dyspnoea and the presence of chest pain.
Finally, both the relatively small number of patients
enrolled and the duration of follow-up in the present study
are other important limitations. Larger studies or registry data
are required to definitively address this issue. On the basis of
these considerations, caution should be used in making
definitive inferences from our results.
Conclusion
In this study MSCT-CA evidence of obstructive CAD
provided incremental information for predicting future
cardiac events in addition to standard risk factor assessment
and presenting symptom characteristics. MSCT-CA with no
evidence of obstructive or non-obstructive CAD was not
associated with any cardiac events during the study period
in both DM and non-DM patients.
The study also demonstrated that dyspnoea is another
important symptom in the assessment of prognosis among
diabetic patients.
In standard assessment, MSCT-CA may give valuable
prognostic information for the evaluation of patients with
suspected CAD, particularly those at low or intermediate
risk of having significant CAD.
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